Figures Data for "Development and Internal Validation of a Novel Pre-Transplant Biomarker Panel to Predict Post-Transplant Mortality in Liver Transplant Recipients"

Figures Data regarding the development and internal validation of the Liver Immune Frailty Index. This study seeks to identify biomarkers of pre-liver transplant (LT) immune dysfunction that predict early mortality following LT. Plasma biomarkers and clinical variables were assessed 279 waitlisted patients immediately prior to LT (T0). HCV IgG, Fractalkine, and MMP3 were multivariate predictors of 1-year mortality. These were utilized to create the Liver Immune Frailty Index (LIFI), which stratifies recipients into -low, -moderate, and –high risk tertiles of early post-LT mortality. One-year mortality was 1.4%, 12.7%, and 58.3% for LIFI-low, -moderate, and -high, respectively. Internal validation demonstrates LIFI predicts early post-LT mortality (C-statistic=0.84, Brier score=0.04). Stratification into LIFI-high or moderate requires cumulative contribution of elevated MMP3 and Fractalkine levels and is not dependent on HCV status. Excluding HCV IgG+ as a covariate similarly stratifies patients at high-, moderate-, and low-risk of early post-LT mortality (LIFIMF, C-statistic 0.83). LIFI may identify patients at risk for persistent severe immune dysfunction and early mortality post-LT.